The US stock market has processed 90 initial public offerings in 2026 as of April 7, a 7.14% increase over the same period last year, when 84 IPOs had priced by that date. That number tells you more about the real state of public markets than any pundit's hot take ever could.
The 2026 IPO Market Is Open, but Barely
Let's put that 90-IPO figure in context. We are talking about roughly 22 new listings per month across the entire US stock market. That is not a flood. It is not a drought either. It sits squarely in the territory analysts call 'functional but cautious.'
Compare this to the frenzy of 2021, when special purpose acquisition companies alone were pushing hundreds of listings through the pipeline. The market has clearly reset since then. Companies are not rushing to go public just because venture capitalists want their exit. They are going public because the math works.
IPO calendar trackers show a steady drumbeat of healthcare, technology, and energy companies filing and pricing. Platforms like Pineify are tracking dozens of additional offerings sitting in the pipeline, waiting for the right window. AccessIPOs lists more than 40 startups in its pipeline tracker, including names like Cerebras, X-Energy, and Discord. These are not fly-by-night operations. These are companies that have been groomed for years, often with multiple private funding rounds behind them.
But here is the thing. The fact that so many companies are still waiting tells you something important. Going public in 2026 is not a guaranteed win. It is a calculated decision, and plenty of founders are still choosing to wait.
What the Numbers Actually Reveal About Market Sentiment
A 7.14% year-over-year increase sounds positive on paper. But dig into what that really means and the picture gets more nuanced. The total count is up, but the composition of those IPOs has shifted dramatically.
Smaller Deals, Realistic Valuations
The standout trend in 2026 is the dominance of acquisition corporations and smaller offerings. Looking at the list of priced deals, a large share are SPACs and blank-check companies pricing at the standard $10 per unit. Encore Medical, which appeared on the April 2026 IPO calendar on NYSE MKT with a $5 per share price and a roughly $17 million offering, is more the exception than the rule. This is the kind of operational deal that defines the non-SPAC portion of the current market: solid businesses, reasonable price tags, no hype circus.
Stocknear's directory of 2026 IPOs lists 183 tracked symbols, though many of those represent filed but not yet priced offerings. The gap between filed and priced is revealing. It means companies are testing the waters, seeing how recently listed peers trade, and adjusting their expectations accordingly.
Venture capital firms have had to accept a new reality. The days of piping a startup through a quick IPO at a massive premium are gone. Exits now require patience, realistic pricing, and often a willingness to leave money on the table to get the deal done.
Healthcare and Energy Are Carrying the Load
Sector distribution matters here. Healthcare companies, particularly biotech firms like Generate Biomedicines, AgomAb Therapeutics, and SpyGlass Pharma, make up a significant share of new listings. Energy companies, including Nine Energy Service and SOLV Energy, are also finding their way to market. These sectors offer something that pure-play software companies often cannot right now: tangible revenue and clear paths to profitability.
Technology startups, by contrast, have been more hesitant. The software-as-a-service multiples that once powered blockbuster IPOs have compressed significantly. That compression has forced a structural shift in how startups plan their public market debuts.
What This Means for the Rest of 2026
The second half of 2026 will be the real test. Spring IPO windows have historically been active, but the summer months can slow things down considerably. If the companies in the pipeline start pricing through summer and into fall, that would signal genuine confidence returning to the market.
But there are risks. Interest rate policy remains a wildcard. Any shift in Federal Reserve positioning could shut the window as quickly as it opened. Institutional investors, who drive IPO allocations, are famously skittish. They will participate in deals they believe in, but they will not support pricing just to make a deal happen.
The most likely scenario is continuation of the current pattern: steady, unspectacular, deliberate. The 90 deals done so far put the market on a moderate pace, well below the peak years but far from dormant. That would be a healthy number by historical standards, even if it feels underwhelming compared to 2021.
For founders contemplating an IPO, the lesson is clear. The market rewards preparation over hype. Companies with clean financials, understandable business models, and realistic valuation expectations are getting done. Those hoping for a premium simply because they exist in a trendy category are learning a different lesson entirely.
For investors, the opportunity is in selectivity. With 90 deals already done and more coming, the sheer volume means quality varies wildly. Doing homework on each deal matters more than it did in 2021, when rising tides lifted everything.
So here is a question worth sitting with: if the IPO market is the ultimate barometer of confidence, does a 7% uptick in listings mean we are recovering, or does it just mean we have accepted the new normal?
Comments